Table 1.
Patient 1 | Patient 2 | |
---|---|---|
Age, yr | 47 | 52 |
Gender | Male | Female |
Past medical history | Traumatic head injury 2018, PEG-fed | Diabetic nephropathy, kidney/pancreas transplant 2011 |
Drug therapy | Meropenem | Tacrolimus, mycophenolate (suspended), meropenem |
Date of COVID-19 diagnosis | April 3, 2020 | March 26, 2020 |
Onset of syndrome, days after COVID diagnosis | 10 | 3 |
Resolution of syndrome, d | 21 | 18 |
Serum sodium, mmol/l | 152 | 138 |
Serum potassium, mmol/l | 3.6 | 2.9 |
Serum creatinine, μmol/l | 154 | 90 |
Baseline serum creatinine, μmol/l | 60 | 62 |
Serum bicarbonate, mmol/l | 30 | 4 |
Serum corrected calcium, mmol/l | 2.56 | 2.41 |
Serum phosphate, mmol/l | 1.83 | 0.18 |
Serum magnesium, mmol/l | 1.03 | 0.56 |
Serum osmolality, mosmol/l | 321 | ND |
CRP, mg/l | 74 | 100 |
Urinary FEPO4, % | ND | 70 |
Urinary retinol binding protein/creatinine ratio | ND | 1540 |
Urinary osmolality, mosmol/l | 264 | ND |
CRP, C-reactive protein; ND, not done; PEG, percutaneous endoscopic gastrostomy.